Safety of an Infant Formula With Hydrolysed Protein in Term Infants

The requested reference [ccf04e2c3ae4075c5e211982218f8e7e48414788] no longer exists in our database. It has been replaced by the current reference: [1ab91e828b29dd031ca74299f2aafb7584bdef63]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
A multi-centre, randomised, double-blind, parallel-group, controlled, prospective, non-inferiority intervention clinical trial is performed to assess the safety and suitability of an infant formula manufactured from extensively hydrolysed protein by showing normal growth of healthy term infants during the first 120 days of life with an optional follow up until 180 days of life.
Epistemonikos ID: 1918c46642e1e4dc187e8fbf844494f1c1a66bd1
First added on: May 08, 2024